Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I.

Antimicrobial Agents and Chemotherapy
E A TrafnyJ Grzybowski

Abstract

The adherence of 27 clinical Pseudomonas aeruginosa strains to collagen type I was investigated by using a solid-phase assay. The influence of free antibiotics (amikacin, gentamicin, piperacillin, bacitracin, and polymyxin B) and liposome-entrapped antibiotics (amikacin and polymyxin B) on bacterial attachment to collagen type I was examined. The greatest inhibitory effect was shown for free and liposomal amikacin, which decreased the attachment of 74 and 100% of tested strains, respectively. The mean percent attachment (+/- standard deviation) in the presence of free amikacin was 65.7% (+/- 12.0%) as measured by solid-phase assay. In the presence of liposomal amikacin, the attachment ranged from 17.3% (+/- 6.0%) to 42.1% (+/- 9.4%), depending on the antibiotic solvent. In contrast, polymyxin B, even at a subinhibitory concentration, enhanced attachment of all P. aeruginosa isolates to collagen. Liposomal polymyxin B displayed a protective effect only when the encapsulated drug was of a low concentration. Application of liposome-encapsulated amikacin may be advantageous in injured tissues in which extracellular matrix structures become exposed.

References

Oct 1, 1976·Immunochemistry·D C Morrison, D M Jacobs
Jun 1, 1991·The Journal of Clinical Investigation·M C PlotkowskiE Puchelle
Dec 1, 1994·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·G Piatti
Aug 1, 1993·Molecular Microbiology·B Westerlund, T K Korhonen
Feb 1, 1994·The Journal of Clinical Investigation·R D Isaacs
Sep 1, 1993·Antimicrobial Agents and Chemotherapy·S T BoyceI A Holder
Sep 1, 1993·Journal of Bacteriology·J L KadurugamuwaT J Beveridge

❮ Previous
Next ❯

Citations

Jan 18, 2003·Journal of Microbiological Methods·Britta SwansonJeanine Wiener-Kronish
Nov 26, 2013·Future Microbiology·Sarah Elizabeth MaddocksRose Agnes Cooper
Dec 30, 2014·Journal of Pharmaceutical Sciences·Rahul S KalhapureThirumala Govender
Dec 9, 2009·International Journal of Pharmaceutics·Zuzanna Drulis-Kawa, Agata Dorotkiewicz-Jach
May 26, 2006·International Wound Journal·Masahiro TachiPhilip Bowler
Aug 18, 2004·Journal of Medical Microbiology·A P FonsecaJ C Sousa
Oct 16, 2004·The Journal of Antimicrobial Chemotherapy·Ashraf A KadryMohsen A Bayomi
Sep 14, 2017·Frontiers in Microbiology·Shahper N KhanAsad U Khan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.